Uterine mullerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy

Case report OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-24 ⓘ

This case report describes a woman who developed uterine mullerian adenosarcoma following adenomyoma during tamoxifen therapy, discussing potential drug-related stimulatory effects on the pre-existing condition.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The clinical and pathologic findings in a 53-year-old woman who developed a uterine adenosarcoma following an adenomyoma are described. During the interval between the diagnosis of adenomyoma and the subsequent diagnosis of adenosarcoma, the patient developed breast carcinoma and received adjuvant chemotherapy that included tamoxifen. The possible stimulatory effects of this drug upon the patient's pre-existing adenomyoma are discussed in view of reports of tamoxifen-associated endometrial carcinoma and uterine sarcomas developing in the setting of estrogen excess.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Carcinoma, Intraductal, Noninfiltrating Endometriosis Tamoxifen Uterine Neoplasms Wilms Tumor Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Carcinoma, Intraductal, Noninfiltrating Carcinoma, Intraductal, Noninfiltrating Carcinoma, Intraductal, Noninfiltrating Carcinoma, Intraductal, Noninfiltrating Carcinoma, Intraductal, Noninfiltrating Cell Transformation, Neoplastic

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:01:19.120492+00:00
unpaywall
last seen: 2026-10-16T06:24:35.758740+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine